Paclitaxel-based chemotherapy targeting cancer stem cells from mono- to combination therapy

Hend M. Nawara, Said M. Afify, Ghmkin Hassan, Maram H. Zahra, Akimasa Seno, Masaharu Seno

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Paclitaxel (PTX) is a chemotherapeutical agent commonly used to treat several kinds of cancer. PTX is known as a microtubule-targeting agent with a primary molecular mechanism that disrupts the dynamics of microtubules and induces mitotic arrest and cell death. Simultaneously, other mechanisms have been evaluated in many studies. Since the anticancer activity of PTX was discovered, it has been used to treat many cancer patients and has become one of the most extensively used anticancer drugs. Regrettably, the resistance of cancer to PTX is considered an extensive obstacle in clinical applications and is one of the major causes of death correlated with treatment failure. Therefore, the combination of PTX with other drugs could lead to efficient therapeutic strategies. Here, we summarize the mechanisms of PTX, and the current studies focusing on PTX and review promising combinations.

Original languageEnglish
Article number500
Issue number5
Publication statusPublished - 2021


  • Anticancer
  • Cancer stem cells
  • Combination therapy
  • Microtubule targeting agent
  • Paclitaxel

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Paclitaxel-based chemotherapy targeting cancer stem cells from mono- to combination therapy'. Together they form a unique fingerprint.

Cite this